The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Gastric cancer (GC) is a leading cause of cancer mortality worldwide.
• METTL3-mediated m6A RNA methylation is implicated in tumor initiation and progression.
• The therapeutic potential of METTL3 inhibition in GC remains largely unexplored.

Purpose of the Study:

• To investigate the role of METTL3 in GC.
• To evaluate the efficacy of STM2457, a METTL3 inhibitor, in treating GC.
• To explore the underlying mechanisms of STM2457 action in GC.

Main Methods:

• Analysis of GC expression data from TCGA and GEO databases.
• In vitro studies on GC cell lines to assess proliferation, migration, apoptosis, and cell cycle.
• In vivo experiments using a subcutaneous xenotransplantation mouse model to evaluate tumor growth inhibition.

Main Results:

• METTL3 expression was analyzed in GC.
• STM2457 significantly suppressed GC cell proliferation and migration.
• STM2457 induced apoptosis and S-phase cell cycle arrest in GC cells.
• STM2457 inhibited tumor growth in vivo.

Conclusions:

• STM2457 demonstrates potent anti-cancer effects against gastric cancer by inhibiting METTL3.
• STM2457 exhibits potential as a therapeutic agent for GC treatment.
• Further clinical investigations of STM2457 for GC are warranted.